NV Therapeutics
Berkeley, US · Founded 2024 · Delaware corporation · 8 employees on LinkedIn · 1 known investors
Novaptix develops non-viral gene writing technology intended to support the development and scaling of gene therapies. The company positions its platform as a way to deliver gene-based treatments to patients without viral vectors.
Founders & leadership
KH
Kevin HoldenExecutive
Board
AK
Audrey KozlovBoard director
DD
Daniel DeverBoard director
DK
Dmitry KuzminBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$3M disclosed across 1 round · 2024
▶$3MraisedMar 2025 · 1 investors · OtherRule 506(b)
▶$3MraisedMar 2025 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Audrey KozlovDirector
- Daniel DeverDirector
- Kevin HoldenExecutive Officer, Director, Promoter
- Dmitry KuzminDirector
- Offering amount
- $7.5M
- Amount sold
- $3M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does NV Therapeutics do?
- Novaptix develops non-viral gene writing technology intended to support the development and scaling of gene therapies. The company positions its platform as a way to deliver gene-based treatments to patients without viral vectors.
- Who are NV Therapeutics's investors?
- NV Therapeutics's investors include 4Bio Ventures.
- How much funding has NV Therapeutics raised?
- NV Therapeutics has disclosed $3M raised across 1 round.
- Where is NV Therapeutics headquartered?
- NV Therapeutics is headquartered in Berkeley, US.